NYSE:IMVIMV Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Imv Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.95 -0.13 (-4.22 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.88Now: $2.95▼$3.0950-Day Range$1.52MA: $2.36▼$3.5352-Week Range$1.35Now: $2.95▼$5.12Volume211,238 shsAverage Volume227,497 shsMarket Capitalization$176.50 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingIMV has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.42, IMV has a potential upside of 151.4% from its current price of $2.95.Amount of Analyst CoverageIMV has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesIMV has received 105 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIMV has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentIMV has received 54.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote “Outperform” if you believe IMV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIMV does not currently pay a dividend.Dividend GrowthIMV does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IMV insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorHealth Technology Current SymbolNYSE:IMV Previous Symbol CUSIPN/A CIKN/A WebN/A Phone(902) 492-1819Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares59,830,000Market Cap$176.50 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable IMV Rates by TradingView Receive IMV News and Ratings via Email Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter. IMV (NYSE:IMV) Frequently Asked Questions How has IMV's stock been impacted by COVID-19 (Coronavirus)? IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMV shares have increased by 23.9% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IMV? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV. When is IMV's next earnings date? IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV. How were IMV's earnings last quarter? Imv Inc (NYSE:IMV) announced its earnings results on Monday, March, 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03. The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.03 million. View IMV's earnings history. What price target have analysts set for IMV? 7 equities research analysts have issued 12 month price objectives for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's stock price to reach $7.42 in the next twelve months. This suggests a possible upside of 151.4% from the stock's current price. View analysts' price targets for IMV. What are Wall Street analysts saying about IMV stock? Here are some recent quotes from research analysts about IMV stock: 1. According to Zacks Investment Research, "IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company's pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. " (3/25/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success)." (6/12/2019) Has IMV been receiving favorable news coverage? News articles about IMV stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMV earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutIMV. Who are some of IMV's key competitors? Some companies that are related to IMV include PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI) and Emblem (EMC). View all competitors. What other stocks do shareholders of IMV own? Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY). Who are IMV's key executives? IMV's management team includes the following people: Frederic Ors, CEO, Director & Chief Business OfficerPierre Labbé, Chief Financial OfficerGabriela Nicola Rosu, Chief Medical OfficerMarianne Stanford, Vice President-ResearchJoseph Sullivan, Senior Vice President-Business Development What is IMV's stock symbol? IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV." Who are IMV's major shareholders? IMV's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (0.43%), First Manhattan Co. (0.17%), Wells Fargo & Company MN (0.04%), JPMorgan Chase & Co. (0.05%), Raymond James & Associates (0.05%) and 1832 Asset Management L.P. (0.03%). Which institutional investors are selling IMV stock? IMV stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co.. Which institutional investors are buying IMV stock? IMV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Wells Fargo & Company MN, JPMorgan Chase & Co., Raymond James & Associates, 1832 Asset Management L.P., and 1832 Asset Management L.P.. How do I buy shares of IMV? Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IMV's stock price today? One share of IMV stock can currently be purchased for approximately $2.95. How big of a company is IMV? IMV has a market capitalization of $176.50 million. How can I contact IMV? The company can be reached via phone at (902) 492-1819. This page was last updated on 6/1/2020 by MarketBeat.com Staff
